---
title: 莫德纳获得美国资金用于禽流感疫苗开发，因为动物感染病例不断增加
date: 2024-07-02T11:30:39.900Z
description: Federal health officials step up efforts to boost jab stockpiles in response to widening outbreak
tags: 
- us
author: ft
---

[原文链接](https://ft.com/content/69eb0a05-7a8f-4e9c-8c1c-c13b21817a49)

莫德纳获得美国资金用于禽流感疫苗开发，因为动物感染病例不断增加

# 现代获得1.76亿美元的资金用于支持其禽流感疫苗的后期试验

**新闻摘要：** 现代确保了美国政府1.76亿美元的资金，以支持其禽流感疫苗的后期试验，因为农场动物，包括几乎每个州的家禽农场和奶牛群，正在发生越来越多的爆发。联邦卫生官员正在加强努力，增加疫苗储备，以应对不断扩大的H5N1禽流感感染。

**要点：**
- **现代的禽流感疫苗** 获得了美国政府1.76亿美元的资金，用于后期试验和潜在的大流行供应增加。
- H5N1禽流感的爆发是近年来最大的爆发，影响了几乎每个州的家禽农场和十多个州的奶牛群。由于接触牛群，三名乳品工人已感染。
- 美国卫生官员将公共卫生风险归类为低风险，但正在加强努力监测其传播并增加疫苗供应，芬兰本月提供了第一支针对农场工人的禽流感疫苗。
- 其他公司，如CSL Seqirus（与Barda合作）、Sanofi和GSK，也拥有H5N1禽流感疫苗在美国的储备。
- 现代的mRNA技术在开发速度和生产可扩展性方面优于其他公司使用的传统蛋白质制造方法。
- 预计很快将公布现代针对H5和H7菌株的中期试验结果，辉瑞也有一种禽流感疫苗处于早期试验阶段。

---

 **Article Summary:** Moderna secures $176 million in US government funding to support late-stage trials of its bird flu vaccine amidst a growing outbreak among farm animals, including poultry farms across almost every state and dairy herds. The federal health officials are increasing efforts to boost vaccine stockpiles due to the widening H5Nebird flu infection.

**Key Points:**
- **Moderna's bird flu vaccine** receives $176 million from US government funding for late-stage trials and potential pandemic supply increase.
- The outbreak of H5N1 bird flu is the largest in recent years, affecting poultry farms across almost every state and dairy herds in a dozen states. Three dairy workers have been infected due to exposure to cattle.
- US health officials classify public health risk as low but are stepping up efforts to monitor its spread and increase vaccine supplies, with Finland offering the first bird flu vaccine for farm workers this month.
- Other companies like CSL Seqirus (partnered with Barda), Sanofi, and GSK also have H5N1 bird flu vaccines in US stockpiles.
- Moderna's mRNA technology offers advantages over traditional protein-based manufacturing methods used by other companies for speed of development and production scalability.
- Results from Moderna’s mid-stage trial targeting H5 and H7 strains are expected soon, while Pfizer also has a bird flu vaccine in early-stage trials.

[Source Link](https://ft.com/content/69eb0a05-7a8f-4e9c-8c1c-c13b21817a49)

